Top 3 Stocks Riding The Hemp Boom

Top 3 Stocks Riding The Hemp Boom

Hemp is booming across the country.

And it’s just getting started.

The numbers are absolutely staggering.

Hemp farmers were licensed to increase hemp fields by 455% last year.

Despite the four-fold increase, CNBC still said, “US farmers struggle to keep up with demand for industrial hemp.”

The reason is because consumers can’t get enough of one of the most valuable hemp extracts.

And investors are taking notice.

Why Hemp?

Cannabidiol, often called just “CBD,” is setting sales record across the country.

CBD is derived from hemp which was legalized in the “Farm Bill.”

As a result, hemp demand is soaring and CBD stocks are becoming some of the fastest rising stocks in the market.

In fact, one of our “Top 3 Hemp Stocks” featured below has already DOUBLED in just two weeks.

But if you look at the future of hemp and CBD, you’ll see there’s a lot more to come.

And investors getting in now could reap massive rewards in the weeks and months ahead.

CBD’s Rise From Worst To First And Beyond

CBD is officially classified as an herbal supplement.

As you probably know, supplements are a big and growing industry.

Altogether vitamins, minerals, protein shakes and all the rest have grown into a $37 BILLION a year industry in the U.S.

And the entire industry is growing at 8% a year.

That’s more than $2 BILLION a year in new sales each and every year.  

Here’s the key part though.

A single hot supplement can soar from nothing to billions of dollars of sales in virtually no time.

For example, a couple years ago I first heard about “fish oil.”

Seemed a bit crazy, but could certainly have some health benefits.

I wasn’t alone in that thinking because today fish oil sales are more than $4 BILLION a year.

That’s how fast things can grow in the supplement business.

And that’s where hemp and CBD come into all this.

Today, all signs point to CBD is joining (and eventually surpassing) many other these other top-selling supplements.

Consider this.

Turmeric has been the number one selling herbal dietary supplement for five years running.

That was until CBD came on the scene.  

Three years ago CBD was the #12 selling herbal supplement.

Two years of 300% annual growth later and CBD is #1.

At this rate, CBD will be the #1 selling supplement (not just the #1 herbal supplement) in no time.

How To Invest In CBD Stocks

This begs the question: where do investors look for opportunities in CBD stocks? Here are three names for investors to watch in this soaring market.


Top CBD Stock #1:
CV Sciences Inc (CVSI)

While many companies are currently dabbling in CBD products and marketing, CV Sciences (US:CVSI) is all about “CBD R&D, formulation and marketing”.

With nearly a decade of experience in bringing CBD products to market, CV Sciences now offers a full-line of hemp-derived CBD-based dietary supplements, targeting numerous areas of health improvement.

Recently, the company obtained USPTO approval for its CBD-based treatment for smokeless tobacco addiction. CV Sciences is targeting three “lanes” for product development: conventional foods, dietary supplements and prescription drugs. Its products are already distributed in over 5,000 U.S. retail outlets.

After a strong run for the stock in 2019, CV Sciences has fallen off sharply, dipping to a low of under $0.30 during the worst of the recent market sell-off.

But it immediately bounced back and more than doubled in just two weeks after the market hit bottom.


Top CBD Stock #2
GW Pharmaceuticals (GWPH)

GW Pharma (US:GWPH) is the a major pharmaceutical company and it betting its future on naturally occurring cannabinoids like CBD.

Its lead drug, Epidiolex, is a licensed and approved CBD-based drug for the treatment of epilepsy. That also means GW Pharma is the world’s largest CBD company.

The global market for epilepsy therapeutics alone is expected to reach USD$9.5 billion by 2023, rising at an 8.20% CAGR from 2018 through 2023.

Epidiolex was recently descheduled by the U.S. DEA as a “controlled substance” meaning it can now be freely prescribed and distributed in the United States. The company has also applied for a “Type II Variation Application” to begin to use Epidiolex as a treatment for Tuberous Sclerosis Complex (TSC).

GW Pharma is already building a sales pipeline for its next pharmaceutical product, Nabiximols (sold as Sativex® outside the U.S.). Available in nearly 30 nations outside the U.S., this is a CBD/THC formulation for the treatment of muscle spasticity for Multiple Sclerosis sufferers.


Top CBD Stock #3:
Canafarma Corporation (CSE:CNFA)

For investors looking for something new in the CBD marketplace, there is Canafarma Corporation (CSE:CNFA).

The company only began public trading on the CSE in March 2020. Canafarma is also a specialist in hemp-derived CBD.

The company offers investors seed-to-sale vertical integration. That starts with Canafarma’s 100-acre hemp farm in New York state, devoted to cost-effective outdoor cultivation. Canafarma’s hemp cultivation operation boast both higher per acre yields (2,320 lbs per acre) than the industry average as well as above-average CBD potency (>14%) in its hemp.

However, while Canafarma has built its own internal supply chain for efficiency, the company’s real focus is on the branded hemp-derived CBD products it produces at the end of this pipeline.


That starts with Yooforic™, Canafarma’s flagship product line. Certified as organic, Yooforic™ is a hemp oil-infused chewing gum. It contains a “full spectrum” hemp oil with patent-pending technology to maximize bioavailability.

Yooforic™ is available as a pure hemp oil product. In addition to a wide range of vitamins and nutrients, Yooforic™ provides consumers with the full spectrum of Omega fatty acids. It is also produced in a topical cream formulation.

The company has launched an aggressive marketing strategy for Yooforic™. They have a Proprietary Marketing Mix driven by a powerful Demand-Marketing Engine. This allows them to get their product directly into consumers hands at a low risk and low cost to the company. By utilizing this mix it increases brand presence and sales at a fraction of the cost of traditional marketing. This strategy has already resulted in sales of over $4M in the first 6 months.

For investors looking for focused exposure to the high-growth opportunities in the CBD market, the companies above are three names in the CBD space that are poised to outperform.

FULL DISCLOSURE: CanaFarma Hemp Products is a client of The Seed Investor.

Hemp 455% –
CNBC – struggling to keep up with demand –
CBD #12 to #1 –

Please see full disclaimers at applicable to all content provided by TSI, wherever published or re-published:
Disclaimer: This release/advertorial is a commercial advertisement and is for general information purposes only. This release/advertorial does not constitute an offer or solicitation to buy or sell any securities or individualized investment advice. This is a native advertisement, meaning it is an informational paid marketing piece. (TSI) makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Please review all investment decisions with a licensed investment advisor. TSI receives payments ranging from approximately $25,000 to $150,000 to publish and/or distribute advertisements on behalf of a company. TSI retains any excess sums after expenses as its compensation. and its owners, operators and affiliates may benefit from any increase in the share prices of the profiled companies. may be paid for services using options or free-trading shares. and/or its owners, operators and affiliates may be selling shares of stock at the same time the profile (or other information) is being disseminated to potential investors; will not advise when it or its affiliates decide to sell. Investors must make all investment decisions based on their own judgment of the market and the particular securities.
This advertorial contains forward-looking statements that involve risks and uncertainties. This advertorial contains or incorporates by reference forward-looking statements, including certain information with respect to plans and strategies of the featured company. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believe(s),” “anticipate(s),” “plan(s),” “expect(s),” “project(s),” “will,” “make,” “told,” “could,” “might,” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual events or actual results of the company to differ materially from these indicated by such forward-looking statements. Certain statements contained herein are forward-looking statements as defined in Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business, financing, business trends, future operating revenues and expenses. There can be no assurance that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the company, or contained in this advertorial are not guarantees of future performance, and that the issuer’s actual results may differ materially from those set forth in the forward-looking statements. We undertake no obligation to update any statements made herein except as required by law. Differences in results can be caused by various factors including, but not limited to, the company’s ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. To reiterate, information presented in this advertorial contains “forward-looking statements.” Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. More information on the company may be found at where readers can review all public filings submitted by the company. is not a certified financial analyst or licensed in the securities industry in any manner. The information in this advertorial is subjective opinion and may not be complete, accurate or current and was paid for, so this could create a conflict of interest.


Published at Fri, 10 Apr 2020 07:06:21 +0000

Be the first to comment

Leave a Reply

Your email address will not be published.